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Introduction: The metabolic syndrome is a global public health issue. Using medication that 
reduces the sympathetic over activity as one o f  the manifestations o f  MS, such as cardioselective (3- 
adrenoblockers o f  the III generation (Nebivolol) and the selective agonist o f  the imidazoline 
receptors subtype 1 (Ii) III generation (Moxonidine) is one o f  the main directions o f  
pharmacotherapy in hypertensive patients with MS.
Purpose and objectives: Highlighting the lipid and glycemic profile modification in hypertensive 
patients with or without metabolic syndrome after treatment with Nebivolol and Moxonidine.
Materials and Methods: The study included 294 hypertensive patients (Hypertension grade I-II 
as recommended by the European Society o f  Cardiology, 2007), o f  which: MS (group I) - 201 patients 
and without MS (group II) - 93 patients (control group). The diagnosis o f  MS was based on the WHO 
recommendations (1998), IDF (2005). In the treatment phase o f the study there were included 191 
patients: 93 patients administered for 2 months - Nebivolol and 98 patients used Moxonidine. The 
gathered material was analyzed statistically by the methods o f  variational and correlational analysis.
Results: The group o f  MS patients had an average age o f  49.57 ± 0.81 years (p>0.05) and the 
group o f  patients with MS had an average age o f  48.86 ± 1.03 (p>0.05). Long-term administration 
o f  Nebivolol in the current study significantly reduced total cholesterol, LDL - cholesterol and 
triglyceride levels in MS patients, while blood glucose levels were not changed. In the patients 
treated with Moxonidine 0.2 mg x 2 twice/day for two months, the glucose profile was statistically 
insignificantly changed: 5,18 ± 0 16 mmol/1 (initial stage) vs. 5.08 ± 0.12 mmol/1 (final stage) 
(p>0.05), but the basal insulinemia at the initial stage o f  treatment vs. the final stage (2 months): 
9.19 ± 0.51 gUI/ml vs. 8.01 ± 0.52 pUI/ml had a significant statistical difference (p<0.05) and the 
average value o f  HOM A ir at the initial vs. the final stage, with a decrease in the insulin resistance 
index: 1.98 ± 0.11 vs. 1.62 ± 0.11, had also a significant statistical difference (p<0.05).The analysis 
o f  lipid indexes in the whole group and groups o f  patients with and without MS showed a 
downward trend for TC, LDL-C, TG, but no changes in HDL-C.
Conclusions: In patients with metabolic syndrome Nebivolol did not influence significantly 
the glucose metabolism and it improved the state o f  the lipid, while M oxonidine did not 
significantly affect lipid metabolism, but improved the indexes o f  the glucose metabolism.
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Introduction: W olf-Parkinson- White syndrome (WPW) is a type o f  ventricular pre-excitation 
realized through an abnormal connection between the atria and the ventricles, known as Kent 
bundle, prior to nodo-hisian depolarization. The disease has a genetic substrate, it develops mainly 
in men, involving a high risk o f  ventricular arrhythmias and sudden death. The incidence o f  WPW 
syndrome is 4 cases per 100,000 persons, while the prevalence is 1-3 cases per 1000 pers. 
Male/female ratio is 1.5-2/1. About 50 % o f  patients with WPW develop tachyarrhythmias; the 
frequency o f  supraventricular tachycardia paroxysms increases from 10% at the age o f  20-39 to 
36% over 60 years. The management o f  the disease depends on the paroxysms frequency and the
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types o f  arrhythmia. We present the clinical case o f  a man with WPW syndrome who develops 
recurrent paroxysmal supraventricular tachycardia, treated since 1997.
Clinical case: Patient L., 52 years old, admitted to the Cardiology Department nr.3 o f  PMSI 
MCH „Holy Trinity” . Diagnose: WPW syndrome. Paroxysmal supraventricular tachycardia. HF I 
NYHA. The complaintspresented on onset: palpitations, inspiratory dyspnea, fatigue. History o f  the 
disease: diagnosed in 1997, when he developed a paroxysm o f  supraventricular tachycardia. 
Arrhythmia paroxysms were the cause o f  repeated hospitalizations -  2-3 times/year while being on 
antiarrhythmic therapy with Amiodarone. On physical examination: The overall condition o f 
medium severity. Clean, normal-colored skin. Vesicular breath sounds, rales missing. Rhythmic 
heart sounds with HR 170 b/min, BP 120/70 mmHg. ECG conclusion: WPW syndrome. 
Supraventricular tachycardia with HR 170 b/min. Normal heart electrical axis. LV repolarization 
disorders. EchoCG: moderate dilatation o f  LA and RA. Induration o f  the aortic walls. LV 
hypertrophy, left ventricular contractile function is preserved. Laboratory analysis without deviation 
from the norm. Treatment: Amiodarone 800mg-intravenously in perfusion until paroxysm 
cessation, with subsequent administration after schema.
Conclusions: Patient L., 52 years with WPW syndrome who develops an arrhythmia paro­
xysm was hospitalized for its cessation and reassessment o f  treatment strategy. Pharmacological 
cardioversion had positive effect. The prognosis is favorable for the patient due to rare paroxysms 
of supraventricular tachycardias with a good response to drug treatment.
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Introduction: Arterial hypertension (AHT)is the most common cause o f  morbidity and mor­
tality in developed societies. Recent data assessed the current prevalence o f  arterial hypertension in 
the world around 30 %.
Materials and Methods: According to the working hypothesis and proposed tasks we 
approached closely the procedure o f  selecting patients on which we would focus our exploration, 
examining a sample o f  150 patients diagnosed with hypertension. The assessment was based on 
questionnaires previously developed under the general and special methods o f  clinical examination. For 
each patient selected was completed an original questionnaire that included: general data, historical data, 
clinical data, laboratory and instrumental examinations performed and supportive treatment. So we 
followed the following inclusion criteria: certain diagnosis o f  hypertension and age>65 years.
Results: We found that patients with predominant isolated systolic arterial hypertension was 
-  36,66 %. The ratio o f  male / female predominance certified women in the study group - 59.33%. 
One o f  the most important criteria that was statistically evaluated is the classification o f  patients 
after BP values. The results show that in the study group predominates isolated systolic 
hypertension - 36,66%, AHT III - 28.66%, AHT gr. II - 32%, AHT gr. I - 2.6%. Laboratory 
evaluation found that the most common ECG abnormalities encountered in elderly patients with 
AHT are HVS (38 %), atrial fibrillation (26%) and reduced FE by echocardiography detect 18.66 % 
cases. From antihypertensive drugs in elderly with arterial hypertension are commonly used 
diuretics: loop (71.33 %), thiazide - like (26,66 %) and aldosterone (24%), angiotensin-converting 
enzyme inhibitors (83.33 %) and the calcium channels blockers (56 %).
Analyzing the treatment o f  the patient we found that most patients receive combination treatment 
of 3 antihypertensive drugs 39,33% (59 patients), the combination o f  two antihypertensives was noted 
in 33,33% (50 patients), the combination o f  four drugs have been reported in 37 patients and 
administration o f  a single drug has been found in 4 patients in the study group.
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